Market Overview

Benzinga's Top Analyst Calls From April 3, 2018

Share:

These headlines first appeared on Benzinga Pro.

  • BMO initiates coverage on TriMas Corporation (NASDAQ: TRS) with an Outperform rating and $33 price target and expects to see double-digit earnings growth form 2018-2019, says, “We believe neither this growth nor the longer-term margin and earnings runways we envisage are appropriately valued in the stock."
  • Bank of America Merrill Lynch lowers Third Point Reinsurance (NYSE: TPRE) price target from $18 to $17 after lower-than-expected Feb. and Mar. returns cut into firm’s 2018-2019 EPS estimates.
  • Buckingham Research Group raised its price target on Square Inc (NYSE: SQ) from $52 to $55 to reflect positive trends that will boost outlook. Firm expects Square to reinvest earnings in upside growth opportunities and views recent tech sell-off as buying opportunity.
  • DA Davidson recommends buying Amazon.com, Inc. (NASDAQ: AMZN) weakness, says retail giant has 'low likelihood' of antitrust headwinds.
  • H.C. Wainwright reiterates Buy rating on Quest Resource Holding Corp (NASDAQ: QRHC); Firm says expanded service offerings through large channel planner affords the company access to “a significant number of small customers that would have been otherwise difficult to reach.”
  • Stifel downgrades Constellation Brands, Inc. (NYSE: STZ) to Hold and lowers price target from $245 to $228, says market is pricing in substantial beats that may be hard to generate.
  • RBC on Bright Horizons Family Solutions Inc (NYSE: BFAM): Despite growth potential, short-term risk/reward less compelling as shares trade near lower end of valuation range. Firm downgraded to Sector Perform.

Related Links

Benzinga's Top Upgrades, Downgrades For April 3, 2018

5 Biggest Price Target Changes For Tuesday

Posted-In: Analyst Color Price Target Analyst Ratings

 

Related Articles (AMZN + BFAM)

View Comments and Join the Discussion!

Fidelity Trims Fees on 3 Bond ETFs

Mid-Afternoon Market Update: Quest Resource Falls Following Q4 Results; Bio-Path Shares Surge